secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001104659-26-004785
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax licenses Matrix-M adjuvant to Pfizer for up to $500M milestones plus royalties
--------------------------------------------------------------------------------

- Upfront payment of $30M in Q1 2026; eligible for up to $500M in milestones ($70M development, $180M sales per field).
- Tiered high mid-single digit royalties on net sales until later of 20 years or patent expiry.
- Non-exclusive worldwide license for up to two infectious disease fields; first field selected, second at Pfizer's option.
- Pfizer controls development, manufacturing, and commercialization; separate supply agreements to be finalized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465926004785/0001104659-26-004785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465926004785/tm263587d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-004785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer